Guardant Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Guardant Health reported that its Guardant Reveal test detected 81% of distant melanoma recurrences in a multicenter study, with 100% specificity. The test also identified ctDNA signals 70.5 days before clinical detection, according to the company.
Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
Guardant Health (GH) was added to the IBD 50 list and Investor's Business Daily Leaderboard. The FDA approved its Guardant360 CDx, pushing shares into a buy zone. The company focuses on precision oncology.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GH (Guardant Health, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GH coverage spans financial news, regulation and insider activity.
In the last 30 days, GH insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($3.3M). The most active reporter was Krognes Steve E. with 4 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive trial data supports Guardant Reveal's clinical utility in melanoma, likely boosting investor sentiment.
Optionality from category-level FDA signaling rather than a direct approval event for GH.
FDA approval of Guardant360 CDx is a regulatory catalyst that can expand adoption and reimbursement, supporting near-term sentiment and commercial outlook.
Adds bullish pressure on Guardant Health.
Insider sale may signal reduced confidence, potential short-term price pressure.
AlphAI scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardant Health reported that its Guardant Reveal test detected 81% of distant melanoma recurrences in a multicenter study, with 100% specificity. The test also identified ctDNA signals 70.5 days before clinical detection, according to the company.
1 min readGrail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
6 min readGuardant Health (GH) was added to the IBD 50 list and Investor's Business Daily Leaderboard. The FDA approved its Guardant360 CDx, pushing shares into a buy zone. The company focuses on precision oncology.
2 min readArk Invest, led by Cathie Wood, bought $24.7M of CoreWeave and $7.25M of Meta Platforms, while selling $40M of its Bitcoin ETF and reducing holdings in AMD, Alphabet, Shopify, and Palantir. The firm also adjusted healthcare and aerospace positions, signaling a shift toward AI infrastructure.
2 min readInsiders at Guardant Health (GH), Geo Group (GEO), Tower Semiconductor (TSEM), TG Therapeutics (TGTX), and GigaCloud (GCT) sold shares. GH saw $3.3M in sales from five insiders. GEO's SVP sold $371K, TSEM's director sold $49K, TGTX's director sold $275K, and GCT's director sold $158K.
1 min readCathie Wood's Ark Invest sold crypto-linked positions including ARK 21Shares Bitcoin ETF (ARKB), Coinbase (COIN), and Circle Internet Group (CRCL) on Monday, then bought CoreWeave (CRWV) shares on Thursday after the company announced new contracts and a funding plan. CRWV stock fell 4% this week. Other notable trades included AeroVironment (AVAV) and Meta Platforms (META).
3 min readGuardant Health (GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for advanced HR-positive, HER2-negative breast cancer. This is the first FDA-approved liquid biopsy for longitudinal ctDNA testing in breast cancer. The approval was supported by clinical trial data showing early detection of ESR1 mutations. The company focuses on precision oncology, using blood and tissue tests to tailor cancer treatments. Investors should monitor the impact on future reve
3 min readChudova Darya (Chief Technology Officer) sold 7,738 shares of Guardant Health, Inc. (GH) at $178.00 ($1.38M total) on 2026-09-15.
1 min readKrognes Steve E. sold 6,674 shares of Guardant Health, Inc. (GH) at an average of $175.74 ($174.46–$177.48, $1.17M total) across 4 trades on 2026-09-16.
1 min readGuardant Health (GH) director Musa Tariq filed a notice to sell 116 shares of common stock, valued at $20,300, under Rule 144. The shares come from equity compensation following a restricted stock lapse. Tariq has sold GH stock multiple times in the past three months, totaling hundreds of thousands in proceeds.
1 min read
